Phaseline

Companies › Neuracle Science

Neuracle Science: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NS101
anti-FAM19A5 antibody; synapse organizer and reverser of synapse dysfunction
FAM19A5Phase 1Seneorineural Deafness–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06249919NS101Phase 1Seneorineural DeafnessOtherMay 2026

Targets

FAM19A5 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.